Sign In
Buy CAPR
$25.33
-0.680 (-2.61%)
At Close: Jun 10, 2026
Deramiocel's Promise Brightens Capricor's Outlook, With Strings Attached
05:08am, Saturday, 07'th Dec 2024
Capricor Therapeutics is advancing deramiocel, an allogeneic cell therapy for DMD-related cardiomyopathy, with a rolling BLA submission and potential FDA approval by 2025. Deramiocel showed significan
Capricor: Additional Deramiocel Data Bodes Well For Initiated Rolling BLA Submission
08:00am, Friday, 06'th Dec 2024
Capricor Therapeutics initiated its rolling BLA submission for Deramiocel to treat Duchenne Muscular Dystrophy Cardiomyopathy, with completion expected before the end of 2024. The company presented pr
Capricor Therapeutics to Present at Upcoming Investor Conferences
04:15pm, Monday, 02'nd Dec 2024
SAN DIEGO, Dec. 02, 2024 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare disea
Capricor Therapeutics, Inc. (CAPR) Q3 2024 Earnings Call Transcript
11:12pm, Wednesday, 13'th Nov 2024
Capricor Therapeutics, Inc. (NASDAQ:CAPR ) Q3 2024 Earnings Conference Call November 13, 2024 4:30 PM ET Company Participants A.J. Bergmann - Chief Financial Officer Linda Marbán - Chief Executive Of
Capricor Therapeutics (CAPR) Reports Q3 Loss, Misses Revenue Estimates
06:11pm, Wednesday, 13'th Nov 2024
Capricor Therapeutics (CAPR) came out with a quarterly loss of $0.38 per share versus the Zacks Consensus Estimate of a loss of $0.34. This compares to loss of $0.25 per share a year ago.
Capricor Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update
04:01pm, Wednesday, 13'th Nov 2024
SAN DIEGO, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare disea
Here's Why Momentum in Capricor (CAPR) Should Keep going
09:51am, Monday, 11'th Nov 2024
Capricor (CAPR) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our s
Is Capricor Therapeutics (CAPR) Outperforming Other Medical Stocks This Year?
10:40am, Thursday, 07'th Nov 2024
Here is how Capricor Therapeutics (CAPR) and Hims & Hers Health, Inc. (HIMS) have performed compared to their sector so far this year.
Earnings Preview: Capricor Therapeutics (CAPR) Q3 Earnings Expected to Decline
11:05am, Tuesday, 05'th Nov 2024
Capricor (CAPR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
SAN DIEGO, Oct. 18, 2024 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare disea
Capricor Therapeutics Announces Pricing of Approximately $75 Million Public Offering of Common Stock
06:00am, Thursday, 17'th Oct 2024
SAN DIEGO, Oct. 17, 2024 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare disea
Capricor Therapeutics Announces Proposed Public Offering of Common Stock
04:17pm, Wednesday, 16'th Oct 2024
SAN DIEGO, Oct. 16, 2024 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare disea
-Data Supports Deramiocel's Sustained Efficacy and Safety in Treating DMD- -Improvements Seen in Multiple Cardiac and Skeletal Endpoints Demonstrating Stabilization of Cardiac and Skeletal Muscle Func
What Makes Capricor (CAPR) a Good Fit for 'Trend Investing'
09:50am, Wednesday, 09'th Oct 2024
If you are looking for stocks that are well positioned to maintain their recent uptrend, Capricor (CAPR) could be a great choice. It is one of the several stocks that passed through our "Recent Price
-Company Plans to Complete Rolling BLA Submission by End of 2024; Application May be Eligible for Priority Review by FDA-
